Type 1 diabetes mellitus and cardiovascular disease: A scientific statement from the American Heart Association and American Diabetes Association

Diabetes Care

Volumn 37, Issue 10, 2014, Pages 2843-2863

  De Ferranti, Sarah D ^a   De Boer, Ian H ^a   Fonseca, Vivian ^a   Fox, Caroline S ^a   Golden, Sherita Hill ^a   Lavie, Carl J ^a   Magge, Sheela N ^a   Marx, Nikolaus ^a   McGuire, Darren K ^a   Orchard, Trevor J ^a   Zinman, Bernard ^a   Eckel, Robert H ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; INSULIN; NIFEDIPINE;

ALBUMINURIA; AMERICAN DIABETES ASSOCIATION; ARTERY WALL; ATHEROSCLEROSIS; AUTONOMIC NEUROPATHY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CONTINUOUS INFUSION; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; GENETICS; GLYCEMIC CONTROL; HUMAN; HYPERTENSION; INCIDENCE; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; LIFESTYLE MODIFICATION; MEDICAL SOCIETY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PREGNANCY; PREVALENCE; RACE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEX DIFFERENCE; SMOKING; SMOKING CESSATION; CARDIOVASCULAR DISEASES; COMPLICATION; DIABETES MELLITUS, TYPE 1; DIABETIC ANGIOPATHIES; MEDICAL RESEARCH; RISK FACTOR; STANDARDS; UNITED STATES;

AMERICAN HEART ASSOCIATION; ATHEROSCLEROSIS; BIOMEDICAL RESEARCH; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 1; DIABETIC ANGIOPATHIES; DISEASE PROGRESSION; HUMANS; INFLAMMATION; RISK FACTORS; UNITED STATES;

EID: 84908174029     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc14-1720     Document Type: Review

References (242)

1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010;33(Suppl. 1)S62-S69.
2. Saruhan-Direskeneli G, Uyar FA, Bas F, et al. HLA-DR and -DQ associations with insulindependent diabetes mellitus in a population of Turkey. Hum Immunol 2000;61 296-302.
3. Achenbach P, Lampasona V, Landherr U, et al. Autoantibodies to zinc transporter 8 and SLC30A8 genotype stratify type 1 diabetes risk. Diabetologia 2009;52 1881-1888.
4. Sobngwi E, Mauvais-Jarvis F, Vexiau P, Mbanya JC, Gautier JF. Diabetes in Africans. Part 2 Ketosis-prone atypical diabetes mellitus. Diabetes Metab 2002;28 5-12.
5. Pozzilli P, Buzzetti R. A new expression of diabetes double diabetes. Trends Endocrinol Metab 2007;18 52-57.
6. Lind M, Bounias I, Olsson M, Gudbjörnsdottir S, Svensson AM, Rosengren A. Glycaemic control and incidence of heart failure in 20, 985 patients with type 1 diabetes an observational study. Lancet 2011;378 140-146.
7. Miki T, Yuda S, Kouzu H, Miura T. Diabetic cardiomyopathy pathophysiology and clinical features. Heart Fail Rev 2013;18 149-166.
8. Soedamah-Muthu SS, Fuller JH, Mulnier HE, Raleigh VS, Lawrenson RA, Colhoun HM. High risk of cardiovascular disease in patients with type 1 diabetes in the U.K. a cohort study using the general practice research database. Diabetes Care 2006;29 798-804.
9. JanghorbaniM, Hu FB, Willett WC, et al. Prospective study of type 1 and type 2 diabetes and risk of stroke subtypes the Nurses' Health Study. Diabetes Care 2007;30 1730-1735.
10. Jonasson JM, Ye W, Spar én P, Apelqvist J, Nyr én O, Brismar K. Risks of nontraumatic lower-extremity amputations in patients with type 1 diabetes a population-based cohort study in Sweden. Diabetes Care 2008;31 1536- 1540.
11. Shankar A, Klein R, Klein BE, Moss SE. Association between glycosylated hemoglobin level and cardiovascular and all-cause mortality in type 1 diabetes. Am J Epidemiol 2007;166 393-402.
12. Roy M, Rendas-Baum R, Skurnick J. Mortality in African-Americans with type 1 diabetes the New Jersey 725. Diabet Med 2006;23 698- 706.
13. Secrest AM, Becker DJ, Kelsey SF, Laporte RE, Orchard TJ. Cause-specific mortality trends in a large population-based cohort with longstanding childhood-onset type 1 diabetes. Diabetes 2010;59 3216-3222.
14. Roger VL, Go AS, Lloyd-Jones DM, et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statisticsd2012 update a report from the American Heart Association. Circulation 2012;125 e2-e220 [published correction appears in Circulation 2012;125 e1002].
15. Krolewski AS, Kosinski EJ, Warram JH, et al. Magnitude and determinants of coronary artery disease in juvenile-onset, insulin-dependent diabetes mellitus. Am J Cardiol 1987;59 750- 755.
16. Libby P, Nathan DM, Abraham K, et al.; National Heart, Lung, and Blood Institute; National Institute of Diabetes and Digestive and Kidney Diseases Working Group on Cardiovascular Complications of Type 1 Diabetes Mellitus. Report of the National Heart, Lung, and Blood Institute-National Institute of Diabetes and Digestive and Kidney Diseases Working Group on Cardiovascular Complications of Type 1 Diabetes Mellitus. Circulation 2005; 111 3489-3493.
17. Deckert T, Poulsen JE, Larsen M. Prognosis of diabetics with diabetes onset before the age of thirty-one. I. Survival, causes of death, and complications. Diabetologia 1978;14 363-370.
18. Schram MT, Chaturvedi N, Fuller JH, Stehouwer CD; EURODIAB Prospective Complications Study Group. Pulse pressure is associated with age and cardiovascular disease in type 1 diabetes the EURODIAB Prospective Complications Study. J Hypertens 2003;21 2035-2044.
19. Conway B, Costacou T, Orchard T. Is glycaemia or insulin dose the stronger risk factor for coronary artery disease in type 1 diabetes Diab Vasc Dis Res 2009;6 223-230.
20. Caccamo G, Bonura F, Bonura F, et al. Insulin resistance and acute coronary syndrome. Atherosclerosis 2010;211 672-675.
21. Klein BE, Klein R, McBride PE, et al. Cardiovascular disease, mortality, and retinal microvascular characteristics in type 1 diabetes Wisconsin Epidemiologic Study of Diabetic Retinopathy. Arch Intern Med 2004;164 1917- 1924.
22. Weis U, Turner B, Gibney J, et al. Long-term predictors of coronary artery disease and mortality in type 1 diabetes. QJM 2001;94 623- 630.
23. Laing SP, Swerdlow AJ, Slater SD, et al. Mortality from heart disease in a cohort of 23, 000 patients with insulin-treated diabetes. Diabetologia 2003;46 760-765.
24. Eckel RH, Eisenbarth GS. Autoimmune diabetes inflames the heart. Sci Transl Med 2012;4 138fs18.
25. Taylor JA, Havari E, McInerney MF, Bronson R, Wucherpfennig KW, Lipes MA. A spontaneous model for autoimmune myocarditis using the human MHC molecule HLA-DQ8. J Immunol 2004;172 2651-2658.
26. Gottumukkala RV, Lv H, Cornivelli L, et al. Myocardial infarction triggers chronic cardiac autoimmunity in type 1 diabetes. Sci Transl Med 2012;4138ra80.
27. Lv H, Havari E, Pinto S, et al. Impaired thymic tolerance to a-myosin directs autoimmunity to the heart in mice and humans. J Clin Invest 2011;121 1561-1573.
28. Moss SE, Klein R, Klein BE; The Wisconsin Epidemiologic Study of Diabetic Retinopathy. The 14-year incidence of lower-extremity amputations in a diabetic population. Diabetes Care 1999;22 951-959.
29. Maser RE, Wolfson SK Jr, Ellis D, et al. Cardiovascular disease and arterial calcification in insulin-dependent diabetes mellitus interrelations and risk factor profiles. Pittsburgh Epidemiology of Diabetes Complications Study-V. Arterioscler Thromb 1991;11 958-965.
30. Olson JC, Erbey JR, Forrest KY, Williams K, Becker DJ, Orchard TJ. Glycemia (or, in women, estimated glucose disposal rate) predict lower extremity arterial disease events in type 1 diabetes. Metabolism 2002;51 248-254.
31. Carter RE, Lackland DT, Cleary PA, et al.; Diabetes Control and Complications Trial Epidemiology of Diabetes Interventions and Complications (DCCTEDIC) Study Research Group. Intensive treatment of diabetes is associated with a reduced rate of peripheral arterial calcification in the Diabetes Control and Complications Trial. Diabetes Care 2007;30 2646- 2648.
32. Adler AI, Erqou S, Lima TA, Robinson AH. Association between glycated haemoglobin and the risk of lower extremity amputation in patients with diabetes mellitus-review and meta-analysis. Diabetologia 2010;53 840-849.
33. Dabelea D, Kinney G, Snell-Bergeon JK, et al.; Coronary Artery Calcification in Type 1 Diabetes Study. Effect of type 1 diabetes on the gender difference in coronary artery calcification a role for insulin resistance The Coronary Artery Calcification in Type 1 Diabetes (CACTI) Study. Diabetes 2003;52 2833-2839.
34. Margeirsdottir HD, Stensaeth KH, Larsen JR, Brunborg C, Dahl-Jørgensen K. Early signs of atherosclerosis in diabetic children on intensive insulin treatment a population-based study. Diabetes Care 2010;33 2043-2048.
35. Järvisalo MJ, Putto-Laurila A, Jartti L, et al. Carotid artery intima-media thickness in children with type 1 diabetes. Diabetes 2002;51 493-498.
36. Yamasaki Y, Kawamori R, Matsushima H, et al. Atherosclerosis in carotid artery of young IDDM patients monitored by ultrasound highresolution B-mode imaging. Diabetes 1994;43 634-639.
37. Dalla Pozza R, Bechtold S, Bonfig W, et al. Age of onset of type 1 diabetes in children and carotid intima medial thickness. J Clin Endocrinol Metab 2007;92 2053-2057.
38. Nathan DM, Lachin J, Cleary P, et al.; Diabetes Control and Complications Trial; Epidemiology of Diabetes Interventions and Complications Research Group. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med 2003;348 2294-2303.
39. Larsen JR, Brekke M, Bergengen L, et al. Mean HbA1c over 18 years predicts carotid intima media thickness in women with type 1 diabetes. Diabetologia 2005;48 776-779.
40. Distiller LA, Joffe BI, Melville V, Welman T, Distiller GB. Carotid artery intima-media complex thickening in patients with relatively longsurviving type 1 diabetes mellitus. J Diabetes Complications 2006;20 280-284.
41. Ogawa Y, Uchigata Y, Iwamoto Y. Progression factors of carotid intima-media thickness and plaque in patients with long-term, earlyonset type 1 diabetes mellitus in Japan simultaneous comparison with diabetic retinopathy. J Atheroscler Thromb 2009;16 821-828.
42. Singh TP, Groehn H, Kazmers A. Vascular function and carotid intimal-medial thickness in children with insulin-dependent diabetes mellitus. J Am Coll Cardiol 2003;41 661-665.
43. Järvisalo MJ, Raitakari M, Toikka JO, et al. Endothelial dysfunction and increased arterial intima-media thickness in children with type 1 diabetes. Circulation 2004;109 1750-1755.
44. Costacou T, Lopes-Virella MF, Zgibor JC, et al. Markers of endothelial dysfunction in the prediction of coronary artery disease in type 1 diabetes. The Pittsburgh Epidemiology of Diabetes Complications Study. J Diabetes Complications 2005;19 183-193.
45. Voulgari C, Psallas M, Kokkinos A, Argiana V, Katsilambros N, Tentolouris N. The association between cardiac autonomic neuropathy with metabolic and other factors in subjects with type 1 and type 2 diabetes. J Diabetes Complications 2011;25 159-167.
46. Vinik AI, Ziegler D. Diabetic cardiovascular autonomic neuropathy. Circulation 2007;115 387-397.
47. Nathan DM, Cleary PA, Backlund JY, et al.; Diabetes Control and Complications TrialEpidemiology of Diabetes Interventions and Complications (DCCTEDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353 2643-2653.
48. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285 2486-2497.
49. Jensen T, Borch-Johnsen K, Kofoed-Enevoldsen A, Deckert T. Coronary heart disease in young type 1 (insulin-dependent) diabetic patients with and without diabetic nephropathy incidence and risk factors. Diabetologia 1987;30 144-148.
50. Pambianco G, Costacou T, Ellis D, Becker DJ, Klein R, Orchard TJ. The 30-year natural history of type 1 diabetes complications the Pittsburgh Epidemiology of Diabetes Complications Study experience. Diabetes 2006;55 1463-1469.
51. Laing SP, Swerdlow AJ, Slater SD, et al. The British Diabetic Association Cohort Study, II cause-specific mortality in patients with insulintreated diabetes mellitus. Diabet Med 1999;16 466-471.
52. Skrivarhaug T, Bangstad HJ, Stene LC, Sandvik L, Hanssen KF, Joner G. Long-term mortality in a nationwide cohort of childhood-onset type 1 diabetic patients in Norway. Diabetologia 2006;49 298-305.
53. Colhoun HM, Rubens MB, Underwood SR, Fuller JH. The effect of type 1 diabetes mellitus on the gender difference in coronary artery calcification. J Am Coll Cardiol 2000;36 2160- 2167.
54. Olson JC, Edmundowicz D, Becker DJ, Kuller LH, Orchard TJ. Coronary calcium in adults with type 1 diabetes a stronger correlate of clinical coronary artery disease in men than in women. Diabetes 2000;49 1571-1578.
55. Bosnyak Z, Nishimura R, Hagan Hughes M, et al. Excess mortality in black compared with white patients with type 1 diabetes an examination of underlying causes. Diabet Med 2005; 22 1636-1641.
56. Walsh MG, Zgibor J, Borch-Johnsen K, Orchard TJ; DiaComp Investigators. A multinational assessment of complications in type 1 diabetes the Dia Mond substudy of complications (DiaComp) level 1. Diab Vasc Dis Res 2006;384-92.
57. Garner P. Type I diabetes mellitus and pregnancy. Lancet 1995;346 157-161.
58. Anderson JM, Savvidou MD, Kaihura C, McEniery CM, Nicolaides KH. Maternal arterial stiffness in pregnancies affected by type 1 diabetes mellitus. Diabet Med 2009;26 1135- 1140.
59. World Health Organization. WHO Recommendations for Prevention and Treatment of Pre-eclampsia and Eclampsia. Geneva, Switzerland, World Health Organization, 2011.
60. Donaghue KC, Robinson J, McCredie R, Fung A, Silink M, Celermajer DS. Large vessel dysfunction in diabetic adolescents and its relationship to small vessel complications. J Pediatr Endocrinol Metab 1997;10 593-598.
61. Wiltshire EJ, Gent R, Hirte C, Pena A, Thomas DW, Couper JJ. Endothelial dysfunction relates to folate status in children and adolescents with type 1 diabetes. Diabetes 2002;51 2282-2286.
62. Haller MJ, Stein J, Shuster J, et al. Peripheral artery tonometry demonstrates altered endothelial function in children with type 1 diabetes. Pediatr Diabetes 2007;8 193-198.
63. Urbina EM, Wadwa RP, Davis C, et al. Prevalence of increased arterial stiffness in children with type 1 diabetes mellitus differs by measurement site and sex the SEARCH for Diabetes in Youth Study. J Pediatr 2010;156 731-737.e1.
64. Peppa-Patrikiou M, Scordili M, Antoniou A, Giannaki M, Dracopoulou M, Dacou-Voutetakis C. Carotid atherosclerosis in adolescents and young adults with IDDM. Relation to urinary endothelin, albumin, free cortisol, and other factors. Diabetes Care 1998;21 1004-1007.
65. Krantz JS, Mack WJ, Hodis HN, Liu CR, Liu CH, Kaufman FR. Early onset of subclinical atherosclerosis in young persons with type 1 diabetes. J Pediatr 2004;145 452-457.
66. Parikh A, Sochett EB, McCrindle BW, Dipchand A, Daneman A, Daneman D. Carotid artery distensibility and cardiac function in adolescents with type 1 diabetes. J Pediatr 2000; 137 465-469.
67. Gunczler P, Lanes R, Lopez E, Esaa S, Villarroel O, Revel-Chion R. Cardiac mass and function, carotid artery intima-media thickness and lipoprotein (a) levels in children and adolescents with type 1 diabetes mellitus of short duration. J Pediatr Endocrinol Metab 2002;15 181-186.
68. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329 977-986.
69. Svoren BM, Volkening LK, Butler DA, Moreland EC, Anderson BJ, Laffel LM. Temporal trends in the treatment of pediatric type 1 diabetes and impact on acute outcomes. J Pediatr 2007;150 279-285.
70. Moreno PR, Murcia AM, Palacios IF, et al. Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus. Circulation 2000;102 2180-2184.
71. Valsania P, Zarich SW, Kowalchuk GJ, Kosinski E, Warram JH, Krolewski AS. Severity of coronary artery disease in young patients with insulin-dependent diabetes mellitus. Am Heart J 1991;122 695-700.
72. Pajunen P, Taskinen MR, Nieminen MS, Syvänne M. Angiographic severity and extent of coronary artery disease in patients with type 1 diabetes mellitus. Am J Cardiol 2000;86 1080-1085.
73. Burke AP, Kolodgie FD, Zieske A, et al. Morphologic findings of coronary atherosclerotic plaques in diabetics a postmortem study. Arterioscler Thromb Vasc Biol 2004;24 1266-1271.
74. Mautner SL, Lin F, Roberts WC. Composition of atherosclerotic plaques in the epicardial coronary arteries in juvenile (type I) diabetes mellitus. Am J Cardiol 1992;70 1264-1268.
75. Djaberi R, Schuijf JD, Boersma E, et al. Differences in atherosclerotic plaque burden and morphology between type 1 and 2 diabetes as assessed by multi slice computed tomography. Diabetes Care 2009;32 1507-1512.
76. Larsen JR, Tsunoda T, Tuzcu EM, et al. Intracoronary ultrasound examinations reveal significantly more advanced coronary atherosclerosis in people with type 1 diabetes than in age- And sex-matched non-diabetic controls. Diab Vasc Dis Res 2007;4 62-65.
77. Kornowski R, Mintz GS, Lansky AJ, et al. Paradoxic decreases in atherosclerotic plaque mass in insulin-treated diabetic patients. Am J Cardiol 1998;81 1298-1304.
78. Larsen J, Brekke M, Sandvik L, Arnesen H, Hanssen KF, Dahl-Jorgensen K. Silent coronary atheromatosis in type 1 diabetic patients and its relation to long-term glycemic control. Diabetes 2002;51 2637-2641.
79. Libby P, Ridker PM, Hansson GK; Leducq Transatlantic Network on Atherothrombosis. Inflammation in atherosclerosis from pathophysiology to practice. J Am Coll Cardiol 2009;54 2129-2138.
80. Hayaishi-Okano R, Yamasaki Y, Katakami N, et al. Elevated C-reactive protein associates with early-stage carotid atherosclerosis in young subjects with type 1 diabetes. Diabetes Care 2002;25 1432-1438.
81. Schölin A, Siegbahn A, Lind L, et al.; Diabetes Incidence Study in Sweden group. CRP and IL-6 concentrations are associated with poor glycemic control despite preserved beta-cell function during the first year after diagnosis of type 1 diabetes. Diabetes Metab Res Rev 2004; 20 205-210.
82. Snell-Bergeon JK, West NA, Mayer-Davis EJ, et al. Inflammatory markers are increased in youth with type 1 diabetes the SEARCH Case- Control study. J Clin Endocrinol Metab 2010;95 2868-2876.
83. Wadwa RP, Kinney GL, Ogden L, et al. Soluble interleukin-2 receptor as a marker for progression of coronary artery calcification in type 1 diabetes. Int J Biochem Cell Biol 2006;38 996- 1003.
84. Cipollone F, Chiarelli F, Davì G, et al. Enhanced soluble CD40 ligand contributes to endothelial cell dysfunction in vitro and monocyte activation in patients with diabetes mellitus effect of improved metabolic control. Diabetologia 2005;48 1216-1224.
85. Katakami N, Kaneto H, Matsuhisa M, et al. Association of soluble CD40 ligand with carotid atherosclerosis in Japanese type 1 diabetic patients. Diabetologia 2006;49 1670-1676.
86. Schaumberg DA, Glynn RJ, Jenkins AJ, et al. Effect of intensive glycemic control on levels of markers of inflammation in type 1 diabetes mellitus in the Diabetes Control and Complications Trial. Circulation 2005;111 2446-2453.
87. Costacou T, Zgibor JC, Evans RW, et al. The prospective association between adiponectin and coronary artery disease among individuals with type 1 diabetes. The Pittsburgh Epidemiology of Diabetes Complications Study. Diabetologia 2005;48 41-48.
88. Maahs DM, Ogden LG, Kinney GL, et al. Low plasma adiponectin levels predict progression of coronary artery calcification. Circulation 2005;111 747-753.
89. Deleted in proof.
90. Orchard TJ, Costacou T. When are type 1 diabetic patients at risk for cardiovascular disease Curr Diab Rep 2010;10 48-54.
91. Miller RG, Costacou T, Orchard TJ. Lipoproteinassociated phospholipase A2, C-reactive protein, and coronary artery disease in individuals with type 1 diabetes and macroalbuminuria. Diab Vasc Dis Res 2010;7 47-55.
92. Katakami N, Matsuhisa M, Kaneto H, Yamasaki Y. Serum endogenous secretory RAGE levels are inversely associated with carotid IMT in type 2 diabetic patients. Atherosclerosis 2007; 190 22-23.
93. Lopes-Virella MF, Carter RE, Gilbert GE, et al.; Diabetes Control and Complications Trial Epidemiology of Diabetes Intervention and Complications Cohort Study Group. Risk factors related to inflammation and endothelial dysfunction in the DCCTEDIC cohort and their relationship with nephropathy and macrovascular complications. Diabetes Care 2008;31 2006- 2012.
94. Lopes-Virella MF, McHenry MB, Lipsitz S, et al.; DCCTEDIC Research Group. Immune complexes containing modified lipoproteins are related to the progression of internal carotid intima-media thickness in patients with type 1 diabetes. Atherosclerosis 2007;190 359-369.
95. Jaffa AA, Usinger WR, McHenry MB, et al.; Diabetes Control and Complications TrialEpidemiology of Diabetes Interventions and Complications Study Group. Connective tissue growth factor and susceptibility to renal and vascular disease risk in type 1 diabetes. J Clin Endocrinol Metab 2008;93 1893-1900.
96. Lajer M, Jorsal A, Tarnow L, Parving HH, Rossing P. Plasma growth differentiation factor-15 independently predicts all-cause and cardiovascular mortality as well as deterioration of kidney function in type 1 diabetic patients with nephropathy. Diabetes Care 2010;33 1567-1572.
97. Lajer M, Tarnow L, Jorsal A, Teerlink T, Parving HH, Rossing P. Plasma concentration of asymmetric dimethylarginine (ADMA) predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy. Diabetes Care 2008;31 747-752.
98. Jorsal A, Tarnow L, Flyvbjerg A, Parving HH, Rossing P, Rasmussen LM. Plasma osteoprotegerin levels predict cardiovascular and all-cause mortality and deterioration of kidney function in type 1 diabetic patients with nephropathy. Diabetologia 2008;51 2100-2107.
99. Gogitidze Joy N, Hedrington MS, Briscoe VJ, Tate DB, Ertl AC, Davis SN. Effects of acute hypoglycemia on inflammatory and pro-athero thrombotic biomarkers in individuals with type 1 diabetes and healthy individuals. Diabetes Care 2010;33 1529- 1535 [published correction appears in Diabetes Care 2010;332129].
100. Wright RJ, Newby DE, Stirling D, Ludlam CA, Macdonald IA, Frier BM. Effects of acute insulin-induced hypoglycemia on indices of inflammation putative mechanism for aggravating vascular disease in diabetes. Diabetes Care 2010;33 1591-1597.
101. de Ferranti S, Mozaffarian D. The perfect storm obesity, adipocyte dysfunction, and metabolic consequences. Clin Chem 2008;54 945-955.
102. Lavie CJ, Milani RV, Ventura HO. Obesity and cardiovascular disease risk factor, paradox, and impact of weight loss. J Am Coll Cardiol 2009;53 1925-1932.
103. Devaraj S, Cheung AT, Jialal I, et al. Evidence of increased inflammation and microcirculatory abnormalities in patients with type 1 diabetes and their role in micro vascular complications. Diabetes 2007;56 2790-2796.
104. Lin J, Glynn RJ, Rifai N, et al. Inflammation and progressive nephropathy in type 1 diabetes in the Diabetes Control and Complications Trial. Diabetes Care 2008;31 2338-2343.
105. Mangge H, Schauenstein K, Stroedter L, Griesl A, Maerz W, Borkenstein M. Low grade inflammation in juvenile obesity and type 1 diabetes associated with early signs of atherosclerosis. Exp Clin Endocrinol Diabetes 2004;112 378-382.
106. Kratzsch J, Deimel A, Galler A, Kapellen T, Klinghammer A, Kiess W. Increased serum soluble leptin receptor levels in children and adolescents with type 1 diabetes mellitus. Eur J Endocrinol 2004;151 475-481.
107. OteroM, Lago R, Gómez R, Lago F, Gómez- Reino JJ, Gualillo O. Leptin a metabolic hormone that functions like a proinflammatory adipokine. Drug News Perspect 2006;19 21-26.
108. Harding SA, Sommerfield AJ, Sarma J, et al. Increased CD40 ligand and platelet-monocyte aggregates in patients with type 1 diabetes mellitus. Atherosclerosis 2004;176 321-325.
109. Gomes MB, Piccirillo LJ, Nogueira VG, Matos HJ. Acute-phase proteins among patients with type 1 diabetes. Diabetes Metab 2003;29 405-411.
110. Bowman BH, Kurosky A. Haptoglobin the evolutionary product of duplication, unequal crossing over, and point mutation. Adv Hum Genet 1982;12 189-261, 453-454.
111. Langlois MR, Delanghe JR. Biological and clinical significance of haptoglobin polymorphism in humans. Clin Chem 1996;42 1589- 1600.
112. Asleh R, Guetta J, Kalet-Litman S, Miller- Lotan R, Levy AP. Haptoglobin genotype- And diabetes-dependent differences in ironmediated oxidative stress in vitro and in vivo. Circ Res 2005;96 435-441.
113. Levy AP, Levy JE, Kalet-Litman S, et al. Haptoglobin genotype is a determinant of iron, lipid peroxidation, and macrophage accumulation in the atherosclerotic plaque. Arterioscler Thromb Vasc Biol 2007;27 134-140.
114. Asleh R, Marsh S, Shilkrut M, et al. Genetically determined heterogeneity in hemoglobin scavenging and susceptibility to diabetic cardiovascular disease. Circ Res 2003;92 1193-1200.
115. Kristiansen M, Graversen JH, Jacobsen C, et al. Identification of the haemoglobin scavenger receptor. Nature 2001;409 198-201.
116. Asleh R, Miller-Lotan R, Aviram M, et al. Haptoglobin genotype is a regulator of reverse cholesterol transport in diabetes in vitro and in vivo. Circ Res 2006;99 1419-1425.
117. Costacou T, Ferrell RE, Orchard TJ. Haptoglobin genotype a determinant of cardiovascular complication risk in type 1 diabetes. Diabetes 2008;57 1702-1706.
118. Costacou T, Ferrell RE, Ellis D, Orchard TJ. Haptoglobin genotype and renal function decline in type 1 diabetes. Diabetes 2009;58 2904-2909.
119. Simpson M, Snell-Bergeon JK, Kinney GL, et al. Haptoglobin genotype predicts development of coronary artery calcification in a prospective cohort of patients with type 1 diabetes. Cardiovasc Diabetol 2011;1099.
120. Blum S, Vardi M, Levy NS, Miller-Lotan R, Levy AP. The effect of vitamin E supplementation on cardiovascular risk in diabetic individuals with different haptoglobin phenotypes. Atherosclerosis 2010;211 25-27.
121. Milman U, Blum S, Shapira C, et al. Vitamin E supplementation reduces cardiovascular events in a subgroup of middle-aged individuals with both type 2 diabetes mellitus and the haptoglobin 2-2 genotype a prospective double-blinded clinical trial. Arterioscler Thromb Vasc Biol 2008; 28 341-347.
122. Levy AP, Gerstein HC, Miller-Lotan R, et al. The effect of vitamin E supplementation on cardiovascular risk in diabetic individuals with different haptoglobin phenotypes. Diabetes Care 2004;27 27-67.
123. Blum S, Milman U, Shapira C, et al. Dual therapy with statins and antioxidants is superior to statins alone in decreasing the risk of cardiovascular disease in a subgroup of middle-aged individuals with both diabetes mellitus and the haptoglobin 2-2 genotype. Arterioscler Thromb Vasc Biol 2008;28 e18-e20.
124. Soranzo N, Spector TD, Mangino M, et al. A genome-wide meta-analysis identifies 22 loci associated with eight hematological parameters in the HaemGen consortium. Nat Genet 2009; 41 1182-1190.
125. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents; National Heart, Lung, and Blood Institute. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents summary report. Pediatrics 2011;128(Suppl. 5) S213-S256.
126. Boudina S, Abel ED. Diabetic cardiomyopathy revisited. Circulation 2007;115 3213-3223.
127. Shivalkar B, Dhondt D, Goovaerts I, et al. Flow mediated dilatation and cardiac function in type 1 diabetes mellitus. Am J Cardiol 2006; 97 77-82.
128. Grandi AM, Piantanida E, Franzetti I, et al. Effect of glycemic control on left ventricular diastolic function in type 1 diabetes mellitus. Am J Cardiol 2006;97 71-76.
129. Chan NN, Vallance P, Colhoun HM. Endothelium-dependent and -independent vascular dysfunction in type 1 diabetes role of conventional risk factors, sex, and glycemic control. Arterioscler Thromb Vasc Biol 2003; 23 1048-1054.
130. Witte DR, Tesfaye S, Chaturvedi N, Eaton SE, Kempler P, Fuller JH; EURODIAB Prospective Complications Study Group. Risk factors for cardiac autonomic neuropathy in type 1 diabetes mellitus. Diabetologia 2005;48 164-171.
131. Shishehbor MH, Hoogwerf BJ, Schoenhagen P, et al. Relation of hemoglobin A1c to left ventricular relaxation in patients with type 1 diabetes mellitus and without overt heart disease. Am J Cardiol 2003;91 1514-1517, A9.
132. Larsen JR, Sjøholm H, Berg TJ, et al. Eighteen years of fair glycemic control preserves cardiac autonomic function in type 1 diabetes. Diabetes Care 2004;27 963-966.
133. Paterson AD, Rutledge BN, Cleary PA, Lachin JM, Crow RS; Diabetes Control and Complications TrialEpidemiology of Diabetes Interventions and Complications Research Group. The effect of intensive diabetes treatment on resting heart rate in type 1 diabetes the Diabetes Control and Complications Trial Epidemiology of Diabetes Interventions and Complications study. Diabetes Care 2007;30 2107-2112.
134. Diabetes Control and Complications Trial Research Group. The effect of intensive diabetes therapy on measures of autonomic nervous system function in the Diabetes Control and Complications Trial (DCCT). Diabetologia 1998; 41 416-423.
135. Aepfelbacher FC, Yeon SB, Weinrauch LA, D'Elia J, Burger AJ. Improved glycemic control induces regression of left ventricular mass in patients with type 1 diabetes mellitus. Int J Cardiol 2004;94 47-51.
136. Weinrauch LA, Burger A, Gleason RE, Lee AT, D'Elia JA. Left ventricular mass reduction in type 1 diabetic patients with nephropathy. J Clin Hypertens (Greenwich) 2005;7 159-164.
137. Lehto S, Rönnemaa T, Pÿorälä K, Laakso M. Poor glycemic control predicts coronary heart disease events in patients with type 1 diabetes without nephropathy. Arterioscler Thromb Vasc Biol 1999;19 1014-1019.
138. Soedamah-Muthu SS, Chaturvedi N, Toeller M, et al.; EURODIAB Prospective Complications Study Group. Risk factors for coronary heart disease in type 1 diabetic patients in Europe the EURODIAB Prospective Complications Study. Diabetes Care 2004;27 530-537.
139. Orchard TJ, Olson JC, Erbey JR, et al. Insulin resistance-related factors, but not glycemia, predict coronary artery disease in type 1 diabetes 10-year follow-up data from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care 2003;26 1374-1379.
140. Forrest KY, Becker DJ, Kuller LH, Wolfson SK, Orchard TJ. Are predictors of coronary heart disease and lower-extremity arterial disease in type 1 diabetes the same A prospective study. Atherosclerosis 2000;148 159-169.
141. Eeg-Olofsson K, Cederholm J, Nilsson PM, et al. Glycemic control and cardiovascular disease in 7, 454 patients with type 1 diabetes an observational study from the Swedish National Diabetes Register (NDR). Diabetes Care 2010; 33 1640-1646.
142. Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group. Epidemiology of Diabetes Interventions and Complications (EDIC). Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort. Diabetes Care 1999;22 99-111.
143. Writing Teamfor the Diabetes Control and Complications TrialEpidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 2003;290 2159-2167.
144. Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group. Effect of intensive diabetes treatment on carotid artery wall thickness in the Epidemiology of Diabetes Interventions and Complications. Diabetes 1999;48 383-390.
145. Cleary PA, Orchard TJ, Genuth S, et al.; DCCTEDIC Research Group. The effect of intensive glycemic treatment on coronary artery calcification in type 1 diabetic participants of the Diabetes Control and Complications Trial Epidemiology of Diabetes Interventions and Complications (DCCTEDIC) Study. Diabetes 2006;55 3556-3565.
146. Stettler C, Allemann S, Jüni P, et al. Glycemic control and macro vascular disease in types 1 and 2 diabetes mellitus meta-analysis of randomized trials. Am Heart J 2006;152 27-38.
147. Shamir R, Kassis H, Kaplan M, Naveh T, Shehadeh N. Glycemic control in adolescents with type 1 diabetes mellitus improves lipid serum levels and oxidative stress. Pediatr Diabetes 2008;9 104-109.
148. Petitti DB, Imperatore G, Palla SL, et al.; SEARCH for Diabetes in Youth Study Group. Serum lipids and glucose control the SEARCH for Diabetes in Youth study. Arch Pediatr Adolesc Med 2007;161 159-165.
149. Conway B, Miller RG, Costacou T, et al. Temporal patterns in overweight and obesity in type 1 diabetes. Diabet Med 2010;27 398- 404.
150. Conway B, Miller RG, Costacou T, et al. Adiposity and mortality in type 1 diabetes. Int J Obes (Lond) 2009;33 796-805.
151. Purnell JQ, Dev RK, Steffes MW, et al. Relationship of family history of type 2 diabetes, hypoglycemia, and autoantibodies to weight gain and lipids with intensive and conventional therapy in the Diabetes Control and Complications Trial. Diabetes 2003;52 2623-2629.
152. Purnell JQ, Hokanson JE, Marcovina SM, Steffes MW, Cleary PA, Brunzell JD. Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure results from the DCCT. Diabetes Control and Complications Trial. JAMA 1998;280 140-146.
153. Shay CM, Secrest AM, Goodpaster BH, Kelsey SF, Strotmeyer ES, Orchard TJ. Regional adiposity and risk for coronary artery disease in type 1 diabetes does having greater amounts of gluteal-femoral adiposity lower the risk Diabetes Res Clin Pract 2010;89 288-295.
154. Kilpatrick ES, Rigby AS, Atkin SL. Insulin resistance, the metabolic syndrome, and complication risk in type 1 diabetes double diabetes in the Diabetes Control and Complications Trial. Diabetes Care 2007;30 707-712.
155. Erbey JR, Kuller LH, Becker DJ, Orchard TJ. The association between a family history of type 2 diabetes and coronary artery disease in a type 1 diabetes population. Diabetes Care 1998;21 610-614.
156. Rodrigues TC, Biavatti K, Almeida FK, Gross JL. Coronary artery calcification is associated with insulin resistance index in patients with type 1 diabetes. Braz J Med Biol Res 2010;43 1084-1087.
157. Schauer IE, Snell-Bergeon JK, Bergman BC, et al. Insulin resistance, defective insulinmediated fatty acid suppression, and coronary artery calcification in subjects with and without type 1 diabetes the CACTI study. Diabetes 2011;60 306-314.
158. Orchard TJ, Chang YF, Ferrell RE, Petro N, Ellis DE. Nephropathy in type 1 diabetes a manifestation of insulin resistance and multiple genetic susceptibilities Further evidence from the Pittsburgh Epidemiology of Diabetes Complication Study. Kidney Int 2002;62 963-970.
159. Orchard TJ, Secrest AM, Miller RG, Costacou T. In the absence of renal disease, 20 year mortality risk in type 1 diabetes is comparable to that of the general population a report from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetologia 2010;53 2312-2319.
160. Maahs DM, Jalal D, McFann K, Rewers M, Snell-Bergeon JK. Systematic shifts in cystatin C between 2006 and 2010. Clin J Am Soc Nephrol 2011;6 1952-1955.
161. Nadeau KJ, Regensteiner JG, Bauer TA, et al. Insulin resistance in adolescents with type 1 diabetes and its relationship to cardiovascular function. J Clin Endocrinol Metab 2010; 95 513-521.
162. Williams KV, Erbey JR, Becker D, Orchard TJ. Improved glycemic control reduces the impact of weight gain on cardiovascular risk factors in type 1 diabetes. The Epidemiology of Diabetes Complications Study. Diabetes Care 1999;22 1084-1091.
163. Slama G. The insulin sparing effect of metformin in insulin-treated diabetic patients. Diabete Metab 1991;17 241-243.
164. The DCCT Research Group. Lipid and lipoprotein levels in patients with IDDM diabetes control and complication. Trial experience. Diabetes Care 1992;15 886-894.
165. Maahs DM, Nadeau K, Snell-Bergeon JK, et al. Association of insulin sensitivity to lipids across the lifespan in people with type 1 diabetes. Diabet Med 2011;28 148-155.
166. Maahs DM, Hokanson JE, Wang H, et al. Lipoprotein sub fraction cholesterol distribution is proatherogenic in women with type 1 diabetes and insulin resistance. Diabetes 2010;59 1771-1779.
167. Pérez A, Wägner AM, Carreras G, et al. Prevalence and phenotypic distribution of dyslipidemia in type 1 diabetes mellitus effect of glycemic control. Arch Intern Med 2000;160 2756-2762.
168. Valabhji J, Donovan J, McColl AJ, Schachter M, Richmond W, Elkeles RS. Rates of cholesterol esterification and esterified cholesterol net mass transfer between high-density lipoproteins and apolipoprotein B-containing lipoproteins in type 1 diabetes. Diabet Med 2002;19 424-428.
169. Soedamah-Muthu SS, Chang YF, Otvos J, Evans RW, Orchard TJ; Pittsburgh Epidemiology of Diabetes Complications Study. Lipoprotein subclass measurements by nuclear magnetic resonance spectroscopy improve the prediction of coronary artery disease in type 1 diabetes. A prospective report from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetologia 2003;46 674- 682.
170. Costacou T, Evans RW, Orchard TJ. Highdensity lipoprotein cholesterol in diabetes is higher always better J Clin Lipidol 2011;5 387-394.
171. Orchard TJ, Forrest KY, Kuller LH, Becker DJ; Pittsburgh Epidemiology of Diabetes Complications Study. Lipid and blood pressure treatment goals for type 1 diabetes 10-year incidence data from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care 2001;24 1053-1059.
172. Cholesterol Treatment Trialists' (CTT) Collaboration; Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol a meta-analysis of data from 170, 000 participants in 26 randomised trials. Lancet 2010;376 1670-1681.
173. Zgibor JC, Wilson RR, Orchard TJ. Has control of hypercholesterolemia and hypertension in type 1 diabetes improved over time Diabetes Care 2005;28 521-526.
174. Hovind P, Tarnow L, Rossing P, et al. Predictors for the development of micro albuminuria and macroalbuminuria in patients with type 1 diabetes inception cohort study. BMJ 2004; 32 81-105.
175. de Boer IH, Rue TC, Cleary PA, et al.; Diabetes Control and Complications Trial Epidemiology of Diabetes Interventions and Complications Study Research Group. Long-term renal outcomes of patients with type 1 diabetes mellitus and micro albuminuria an analysis of the Diabetes Control and Complications Trial Epidemiology of Diabetes Interventions and Complications cohort. Arch Intern Med 2011;171 412-420.
176. Bojestig M, Arnqvist HJ, Hermansson G, Karlberg BE, Ludvigsson J. Declining incidence of nephropathy in insulin-dependent diabetes mellitus. N Engl J Med 1994;330 15-18 [published correction appears in N Engl J Med 1994; 330584].
177. Molitch ME, Steffes M, Sun W, et al.; Epidemiology of Diabetes Interventions and Complications Study Group. Development and progression of renal insufficiency with and without albuminuria in adultswith type 1 diabetes in the Diabetes Control and Complications Trial and the Epidemiology of Diabetes Interventions and Complications Study. Diabetes Care 2010; 33 1536-1543.
178. Perkins BA, Ficociello LH, Ostrander BE, et al. Micro albuminuria and the risk for early progressive renal function decline in type 1 diabetes. J Am Soc Nephrol 2007;18 1353-1361.
179. Groop PH, Thomas MC, Moran JL, et al.; FinnDiane Study Group. The presence and severity of chronic kidney disease predicts allcause mortality in type 1 diabetes. Diabetes 2009;58 1651-1658.
180. Borch-Johnsen K, Kreiner S. Proteinuria value as predictor of cardiovascular mortality in insulin dependent diabetes mellitus. Br Med J (Clin Res Ed) 1987;294 1651-1654.
181. Torffvit O, Lövestam-Adrian M, Agardh E, Agardh CD. Nephropathy, but not retinopathy, is associated with the development of heart disease in type 1 diabetes a 12-year observation study of 462 patients. Diabet Med 2005;22 723- 729.
182. Kim WY, Astrup AS, Stuber M, et al. Subclinical coronary and aortic atherosclerosis detected by magnetic resonance imaging in type 1 diabetes with and without diabetic nephropathy. Circulation 2007;115 228-235.
183. Newman DJ, Mattock MB, Dawnay AB, et al. Systematic review on urine albumin testing for early detection of diabetic complications. Health Technol Assess 2005;9 iii-vi, xiii-163.
184. Tuomilehto J, Borch-Johnsen K, Molarius A, et al. Incidence of cardiovascular disease in type 1 (insulin-dependent) diabetic subjects with and without diabetic nephropathy in Finland. Diabetologia 1998;41 784-790.
185. Soedamah-Muthu SS, Chaturvedi N, Witte DR, Stevens LK, Porta M, Fuller JH; EURODIAB Prospective Complications Study Group. Relationship between risk factors and mortality in type 1 diabetic patients in Europe the EURODIAB Prospective Complications Study (PCS). Diabetes Care 2008;31 1360-1366.
186. Drury PL, Ting R, Zannino D, et al. Estimated glomerular filtration rate and albuminuria are independent predictors of cardiovascular events and death in type 2 diabetes mellitus the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetologia 2011;54 32-43.
187. Nathan DM, Zinman B, Cleary PA, et al.; Diabetes Control and Complications TrialEpidemiology of Diabetes Interventions and Complications (DCCTEDIC) Research Group. Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration the Diabetes Control and Complications TrialEpidemiology of Diabetes Interventions and Complications and Pittsburgh Epidemiology of Diabetes Complications experience (1983-2005). Arch Intern Med 2009;169 1307-1316.
188. de Boer IH, Katz R, Cao JJ, et al. Cystatin C, albuminuria, and mortality among older adults with diabetes. Diabetes Care 2009;32 1833- 1838.
189. Matsushita K, van der Velde M, Astor BC, et al.; Chronic Kidney Disease Prognosis Consortium. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts a collaborative meta-analysis. Lancet 2010;375 2073-2081.
190. Maahs DM, Ogden LG, Kretowski A, et al. Serum cystatin C predicts progression of subclinical coronary atherosclerosis in individuals with type 1 diabetes. Diabetes 2007;56 2774- 2779.
191. de Boer IH, Rue TC, Hall YN, Heagerty PJ, Weiss NS, Himmelfarb J. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA 2011;305 2532-2539.
192. Ninomiya T, Perkovic V, de Galan BE, et al.; ADVANCE Collaborative Group. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 2009;20 1813-1821.
193. Orchard TJ, Costacou T, Kretowski A, Nesto RW. Type 1 diabetes and coronary artery disease. Diabetes Care 2006;29 2528-2538.
194. Sibal L, Agarwal SC, Schwedhelm E, Lüneburg N, Böger RH, Home PD. A study of endothelial function and circulating asymmetric dimethylarginine levels in people with type 1 diabetes without macro vascular disease or micro albuminuria. Cardiovasc Diabetol 2009;827.
195. Grassi MA, Tikhomirov A, Ramalingam S, Below JE, Cox NJ, Nicolae DL. Genome-wide meta-analysis for severe diabetic retinopathy. Hum Mol Genet 2011;20 2472-2481.
196. Williams WW, Salem RM, McKnight AJ, et al.; GENIE Consortium. Association testing of previously reported variants in a large casecontrol meta-analysis of diabetic nephropathy. Diabetes 2012;61 2187-2194.
197. Sandholm N, Salem RM, McKnight AJ, et al.; DCCTEDIC Research Group. New susceptibility loci associated with kidney disease in type 1 diabetes. PLoS Genet 2012;8 e1002921.
198. Rotival M, Zeller T, Wild PS, et al.; Cardiogenics Consortium. Integrating genome-wide genetic variations and monocyte expression data reveals trans-regulated gene modules in humans. PLoS Genet 2011;7 e1002367.
199. de Boer IH, Sun W, Cleary PA, et al.; DCCT EDIC Research Group. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med 2011;365 2366-2376.
200. Wilmer WA, Hebert LA, Lewis EJ, et al. Remission of nephrotic syndrome in type 1 diabetes long-term follow-up of patients in the Captopril Study. Am J Kidney Dis 1999;34 308- 314.
201. Maahs DM, Kinney GL, Wadwa P, et al. Hypertension prevalence, awareness, treatment, and control in an adult type 1 diabetes population and a comparable general population. Diabetes Care 2005;28 301-306.
202. Rodriguez BL, Dabelea D, Liese AD, et al.; SEARCH Study Group. Prevalence and correlates of elevated blood pressure in youth with diabetes mellitus the SEARCH for Diabetes in Youth Study. J Pediatr 2010;157 245- 251, e1.
203. de Boer IH, Kestenbaum B, Rue TC, et al.; Diabetes Control and Complications Trial (DCCT)Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group. Insulin therapy, hyperglycemia, and hypertension in type 1 diabetes mellitus. Arch Intern Med 2008;168 1867-1873.
204. Chillar ón JJ, Sales MP, Flores-Le-Roux JA, et al. Insulin resistance and hypertension in patients with type 1 diabetes. J Diabetes Complications 2011;25 232-236.
205. Collado-Mesa F, Colhoun HM, Stevens LK, et al. Prevalence and management of hypertension in type 1 diabetes mellitus in Europe the EURODIAB IDDM Complications Study. Diabet Med 1999;16 41-48.
206. Orchard TJ, Stevens LK, Forrest KY, Fuller JH. Cardiovascular disease in insulin dependent diabetes mellitus similar rates but different risk factors in the US compared with Europe. Int J Epidemiol 1998;27 976-983.
207. The European Study for the Prevention of Renal Disease in Type 1 Diabetes (ESPRIT) Study Group. Effect of 3 years of antihypertensive therapy on renal structure in type 1 diabetic patients with albuminuria the European Study for the Prevention of Renal Disease in Type 1 Diabetes (ESPRIT). Diabetes 2001;50 843-850.
208. American Diabetes Association. Standards of medical care in diabetes 2013. Diabetes Care 2013;36(Suppl. 1)S11-S66.
209. Sinaiko AR, Gomez-Marin O, Prineas RJ. Effect of low sodium diet or potassium supplementation on adolescent blood pressure. Hypertension 1993;21 989-994.
210. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 2004;114(2 Suppl. 4th Report)555- 576.
211. Silverstein J, Klingensmith G, Copeland K, et al.; American Diabetes Association. Care of children and adolescents with type 1 diabetes a statement of the American Diabetes Association. Diabetes Care 2005;28 186-212.
212. Chiarelli F, Trotta D, Verrotti A, Mohn A. Treatment of hypertension and micro albuminuria in children and adolescents with type 1 diabetes mellitus. Pediatr Diabetes 2002;3 113-124.
213. Rooke TW, Hirsch AT, Misra S, et al.; American College of Cardiology Foundation American Heart Association Task Force on Practice Guidelines; Society for Cardiovascular Angiography and Interventions; Society of Interventional Radiology; Society for Vascular Medicine; Society for Vascular Surgery. 2011 ACCFAHA focused update of the guideline for the management of patients with peripheral artery disease (updating the 2005 guideline) a report of the American College of Cardiology Foundation American Heart Association Task Force on Practice Guidelines developed in collaborationwith the Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society for Vascular Medicine, and Society for Vascular Surgery. J Vasc Surg 2011; 54 e32-e58.
214. Christiansen E, Madsbad S. [Smoking and diabetes mellitus]. Ugeskr Laeger 1989;151 3050-3053 [in Danish].
215. Eliasson B. Cigarette smoking and diabetes. Prog Cardiovasc Dis 2003;45 405-413.
216. Schwab KO, Doerfer J, Hallermann K, et al. Marked smoking-associated increase of cardiovascular risk in childhood type 1 diabetes. Int J Adolesc Med Health 2008;20 285-292.
217. Tonstad S. Cigarette smoking, smoking cessation, and diabetes. Diabetes Res Clin Pract 2009;85 4-13.
218. Cadario F, Prodam F, Pasqualicchio S, et al. Lipid profile and nutritional intake in children and adolescents with type 1 diabetes improve after a structured dietician training to a Mediterraneanstyle diet. J Endocrinol Invest 2012;35 160-168.
219. Rodriguez BL, Fujimoto WY, Mayer-Davis EJ, et al. Prevalence of cardiovascular disease risk factors in U.S. children and adolescents with diabetes the SEARCH for Diabetes in Youth Study. Diabetes Care 2006;29 1891-1896.
220. Margeirsdottir HD, Larsen JR, Brunborg C, Overby NC, Dahl-Jørgensen K; Norwegian Study Group for Childhood Diabetes. High prevalence of cardiovascular risk factors in children and adolescents with type 1 diabetes a population-based study. Diabetologia 2008; 51 554-561.
221. Schwab KO, Doerfer J, Hecker W, et al.; DPV Initiative of the German Working Group for Pediatric Diabetology. Spectrum and prevalence of atherogenic risk factors in 27, 358 children, adolescents, and young adults with type 1 diabetes cross-sectional data from the German diabetes documentation and quality management system (DPV). Diabetes Care 2006;29 218-225.
222. Schwab KO, Doerfer J, Marg W, Schober E, Holl RW; DPV Science Initiative and the Competence Network Diabetes Mellitus. Characterization of 33, 488 children and adolescents with type 1 diabetes based on the gender-specific increase of cardiovascular risk factors. Pediatr Diabetes 2010;11 357-363.
223. Maahs DM, Wadwa RP, McFann K, et al. Longitudinal lipid screening and use of lipidlowering medications in pediatric type 1 diabetes. J Pediatr 2007;150 146-150, 150e1-2.
224. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of obesity and trends in body mass index among US children and adolescents, 1999-2010. JAMA 2012;307 483-490.
225. Luczyński W, Szypowska A, Bossowski A, et al. [Overweight, obesity and metabolic syndrome in children with type 1 diabetes melllitus]. Pediatr Endocrinol Diabetes Metab 2010; 16 83-88 [in Polish].
226. van VlietM, Van der Heyden JC, DiamantM, et al. Overweight is highly prevalent in children with type 1 diabetes and associates with cardio metabolic risk. J Pediatr 2010;156 923-929.
227. van Vliet M, van der Heyden JC, Diamant M, et al. Overweight children with type 1 diabetes have a more favourable lipid profile than overweight non-diabetic children. Eur J Pediatr 2012;171 493-498.
228. Daniels SR, Greer FR; Committee on Nutrition. Lipid screening and cardiovascular health in childhood. Pediatrics 2008;122 198-208.
229. Kavey RE, Allada V, Daniels SR, et al.; American Heart Association Expert Panel on Population and Prevention Science; American Heart Association Council on Cardiovascular Disease in the Young; American Heart Association Council on Epidemiology and Prevention; American Heart Association Council on Nutrition, Physical Activity and Metabolism; American Heart Association Council on High Blood Pressure Research; American Heart Association Council on Cardiovascular Nursing; American Heart Association Council on the Kidney in Heart Disease; Interdisciplinary Working Group on Quality of Care and Outcomes Research. Cardiovascular risk reduction in high-risk pediatric patients a scientific statement from the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research endorsed by the American Academy of Pediatrics. Circulation 2006;114 2710-2738.
230. Salem MA, Aboelasrar MA, Elbarbary NS, Elhilaly RA, Refaat YM. Is exercise a therapeutic tool for improvement of cardiovascular risk factors in adolescents with type 1 diabetes mellitus A randomised controlled trial. Diabetol Metab Syndr 2010;247.
231. Haller MJ, Stein JM, Shuster JJ, et al. Pediatric Atorvastatin in Diabetes Trial (PADIT) a pilot study to determine the effect of atorvastatin on arterial stiffness and endothelial function in children with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 2009;22 65-68.
232. McCrindle BW, Urbina EM, Dennison BA, et al.; American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee; American Heart Association Council of Cardiovascular Disease in the Young; American Heart Association Council on Cardiovascular Nursing. Drug therapy of high-risk lipid abnormalities in children and adolescents a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing. Circulation 2007;115 1948-1967.
233. Adolescent type 1 Diabetes cardio-renal Intervention Trial Research Group. Adolescent type 1 Diabetes Cardio-renal Intervention Trial (AdDIT). BMC Pediatr 2009;979.
234. Greenland P, Alpert JS, Beller GA, et al.; American College of Cardiology Foundation American Heart Association Task Force on Practice Guidelines. 2010 ACCFAHA guideline for assessment of cardiovascular risk in asymptomatic adults a report of the American College of Cardiology Foundation American Heart Association Task Force on Practice Guidelines. Circulation 2010;122 e584-e636.
235. Zgibor JC, Piatt GA, Ruppert K, Orchard TJ, Roberts MS. Deficiencies of cardiovascular risk prediction models for type 1 diabetes. Diabetes Care 2006;29 1860-1865.
236. Zgibor JC, Ruppert K, Orchard TJ, et al. Development of a coronary heart disease risk prediction model for type 1 diabetes the Pittsburgh CHD in Type 1 Diabetes Risk Model. Diabetes Res Clin Pract 2010;88 314-321.
237. Zgibor JC, Orchard TJ, Saul M, et al. Developing and validating a diabetes database in a large health system. Diabetes Res Clin Pract 2007;75 313-319.
238. American Diabetes Association. Standards of medical care in diabetes 2011. Diabetes Care 2011;34(Suppl. 1)S11-S61.
239. Snell-Bergeon JK, Hokanson JE, Kinney GL, et al. Measurement of abdominal fat by CT compared to waist circumference and BMI in explaining the presence of coronary calcium. Int J Obes Relat Metab Disord 2004;28 1594- 1599.
240. Greenland P, Bonow RO, Brundage BH, et al.; American College of Cardiology Foundation Clinical Expert Consensus Task Force (ACCFAHA Writing Committee to Update the 2000 Expert Consensus Document on Electron Beam Computed Tomography); Society of Atherosclerosis Imaging and Prevention; Society of Cardiovascular Computed Tomography. ACCF AHA 2007 clinical expert consensus document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain a report of the American College of Cardiology Foundation Clinical Expert Consensus Task Force (ACCFAHA Writing Committee to Update the 2000 Expert Consensus Document on Electron Beam Computed Tomography). Circulation 2007;115 402-426.
241. Raggi P, Shaw LJ, Berman DS, Callister TQ. Prognostic value of coronary artery calcium screening in subjects with and without diabetes. J Am Coll Cardiol 2004;43 1663-1669.
242. Rask-Madsen C, King GL. Mechanisms of disease endothelial dysfunction in insulin resistance and diabetes. Nat Clin Pract Endocrinol Metab 2007;3 46-56.